Durán-Hernández S, Soto-Rodríguez JF, Allen-Bobadilla J, Durán-Hernández N, García-Mosco P

Language: Spanish
References: 17
Page: 56-61
PDF size: 132.87 Kb.

ABSTRACT

Introduction: Osteoarthritis (OA) of the hip is a low-grade inflammatory disease of multiple etiology that has a limited conservative management and insufficiently explored. The application of botulinum toxin type A (BoNT-A) produces in the applied muscle a temporary, delimitable and reversible flaccid paralysis, which applicated in a strategic way achives to reduce mechanical stress and pain. Objective: To evaluate the effect on pain perception, functionality and rigidity and changes in flexibility, internal and external rotation, before and 90 days after the application of BoNT-A. Methods: Clinical, experimental, longitudinal, open study, with a total of 35 patients and 45 hips treated. BoNT-A of 500 U was applied in iliac, adductor brevis and longus muscles. Results: The Wilcoxon test was used to compare the evaluation scores on days 0-90, observing the decrease in referred pain (p ‹ 0.0001), rigidity (p ‹ 0.002), improved perceived function (p ‹ 0.001) and mobility arcs: flexion, internal and external rotation (p ‹ 0.0001). Conclusions: The treatment with BoNT-A provides a conservative and safe option for the management of symptoms and physical restraint caused by hip OA.

REFERENCES

1. National Clinical Guideline Centre. National Institute for Health and Clinical Excellence: Guidance. En: Osteoarthritis: Care and management in adults. Londres, Reino Unido: National Institute for Health and Care Excellence; 2014.

2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-59.

3. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323-30.

4. Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA. Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis- attributable activity limitation among US adults, 2015-2040. Arthritis Rheumatol. 2016;68:1582-7.

5. Atención del paciente con osteoartritis de cadera y rodilla en el primer nivel. Secretaria de Salud Mexico [Internet]. México: gob.mx [fecha de última actualición: marzo de 2014]. Disponible en: https //cenetec-difusion com/gpc-sns/?p=1287.

6. Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol. 2011;86:3-8.

7. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991; 34:505-14.

8. Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12:580-92.

9. Ospelt C, Frank-Bertoncelj M. Why location matters - site-specific factors in rheumatic diseases. Nat Rev Rheumatol. 2017;13:433-42.

10. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:465-74.

11. Kollberg G, Lundholm G. The Voss operation in osteoarthritis of the hip. Acta Orthop Scand. 1965;36:82-8.

12. Filipovic B, Matak I, Bach-Rojecky L, Lackovic Z. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One. 2012;7:e29803.

13. Marinelli S, Vacca V, Ricordy R, Uggenti C, Tata AM, Luvisetto S, et al. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One. 2012;7:e47977.

14. Marchini C, Acler M, Bolognari MA, Causero A, Volpe D, Regis D, et al. Efficacy of botulinum toxin type A treatment of functional impairment of degenerative hip joint: Preliminary results. J Rehabil Med;42 691-3.

15. Boon AJ, Smith J, Dahm DL, Sorenson EJ, Larson DR, Fitz-Gibbon PD, et al. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM & R: the journal of injury, function, and rehabilitation. 2010;2:268-76.

16. Cubillos O, Maldonado A, Moyano Vera Á, San Martín E. Toxina botulínica y su importancia en el campo de la rehabilitación . Rev Hosp Clín Univ Chile 2010; 21: 319 - 25.

17. Cuevas-Trisan R, Motta-Valencia KJ. Botulinum toxins for pain management: A comprehensive review. J Rehabil Med. 2013;1:51-64.